Jade Biosciences (JBIO) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Jade Biosciences (JBIO) has outperformed Savara (SVRA) over the past year, gaining 43.8% versus a gain of 23.3%. Over five years, SVRA leads with a +267.8% price change compared with -97.1% for JBIO. Savara is the larger company by market cap ($914.3 million vs $856.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JBIO | SVRA |
|---|---|---|
| Share price | $13.47 | $4.45 |
| Market cap | $856.66M | $914.30M |
| 1-day change | -2.11% | -6.12% |
| YTD return | -12.70% | -26.20% |
| 1-year return | +43.76% | +23.27% |
| 5-year return | -97.10% | +267.77% |
| EPS (TTM) | $-1.92 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-127.41M | $-118.84M |
| 52-week high | $28.00 | $7.01 |
| 52-week low | $8.36 | $3.60 |
| Distance from 52-week high | -51.89% | -36.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +272.16% | +148.54% |
| Average volume | 899.07K | 1.90M |
| Shares outstanding | 63.60M | 205.46M |
| Employees | 55 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JBIO has outperformed SVRA by 20.5 percentage points over the past year.
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
JBIO vs SVRA FAQ
Which is bigger, Jade Biosciences or Savara?
Savara (SVRA) is larger, with a market capitalization of $914.30M compared with $856.66M for Jade Biosciences (JBIO).
Which stock has performed better over the past year, JBIO or SVRA?
JBIO returned +43.76% over the past 12 months, compared with +23.27% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Jade Biosciences and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.